Opakované ozařování u high-grade gliomů – stále diskutované téma

Stiahnuť PDF English version

Autori: C. C. Mirestean ¹; R. I. Iancu ^2,3; D. P. T. Iancu ^1,2
Pôsobisko autorov: Regional Institute of Oncology, Iasi, Romania ¹; “Gr. T. Popa” University of Medicine, and Pharmacy, Iasi, Romania ²; “St. Spiridon” Emergency Universitary, Hospital, Iasi, Romania, All authors contributed equally. ³
Vyšlo v časopise: Cesk Slov Neurol N 2025; 88(2): 89-94
Kategória: Přehledný referát
doi: https://doi.org/10.48095/cccsnn202589

Súhrn

I po maximální standardní léčbě, která zahrnuje maximální chirurgickou resekci, adjuvantní radioterapii a souběžnou a následně adjuvantní chemoterapii alkylační látkou temozolomidem (TMZ), což je režim ověřený klinickými studiemi fáze III, zůstává celkové přežití u glioblastomu (GB), nejčastějšího a nejmalignějšího podtypu gliomu vysokého stupně, omezené. Pětileté přežití je nižší než 10 %, přičemž obvyklou příčinou úmrtí je lokální recidiva. Nejčastěji navrhovanými alternativami čistě paliativní léčby jsou reoperace, opětovné podání alkylačních látek včetně TMZ nebo léčba relapsu lomustinem a opakované ozařování. Opakované ozařování se jeví být možností pro GB v pečlivě vybraných případech a volba ozařovací metody mezi standardní frakcionací, stereotaktickou hypofrakcionovanou radioterapií a stereotaktickou radiochirurgií musí zohledňovat technické a s pacientem související faktory a průběh relapsu. Použití alkylačních látek TMZ a lomustinu v kombinaci s opakovaným ozařováním se zdá být strategií s přínosem zejména po výběru terapie na základě metylačního stavu promotoru O6-metylguanin-DNA-metyltransferázy. Budoucími směry výzkumu jsou neoadjuvantní imunoterapie a identifikace molekulárních biomarkerů, přesnější vymezení cílového objemu na základě pozitronové emisní tomografie/výpočetní tomografie s aminokyselinami, ale také použití inhibitorů glykolýzy ve spojení s látkami proti cévnímu endoteliálnímu růstovému faktoru. Omezení kumulativních ekvivalentních dávek po 2 Gy (EQD2) na mozkovou tkáň parenchym do výše 100 Gy v případě ultrahypofrakcionovaných režimů a do výše < 120 Gy EQD2 v případě jiných frakcionačních schémat by mohlo omezit riziko mozkové radionekrózy pod 10 %.

Klíčová slova:

radioterapie – glioblastom – stereotaktická radiochirurgie – opakované ozařování – O6-methyl-guanin-DNA-metyltransferáza – temozolomide – lomustin – hypofrakcionovaná stereotaktická radioterapie – radionekróza

Zdroje

1. Birk HS, Han SJ, Butowski NA. Treatment options for recurrent high-grade gliomas. CNS Oncol 2017; 6 (1): 61–70. doi: 10.2217/cns-2016-0013.

2. Apuzzo MLJ. Malignant cerebral glioma. American Association of Neurological Surgeons; Park Ridge, USA: 1990. pp. 79–89.

3. Pranckeviciene A, Bunevicius A. Depression screening in patients with brain tumors: a review. CNS Oncol 2015; 4 (2): 71–78. doi: 10.2217/cns.14.60.

4. Salari N, Ghasemi H, Fatahian R et al. The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis. Eur J Med Res 2023; 28 (1): 39. doi: 10.1186/s40001-023-01011-y.

5. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10): 987–996. doi: 10.1056/NEJMoa043330.

6. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10 (5): 459–466. doi: 10.1016/S1470-2045 (09) 70025-7.

7. Fabbro-Peray P, Zouaoui S, Darlix A et al. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. J Neurooncol 2019; 142 (1): 91–101. doi: 10.1007/s11060-018-03065-z.

8. Weller M, Cloughesy T, Perry JR et al. Standards of care for treatment of recurrent glioblastoma – are we there yet? Neuro Oncol 2013; 15 (1): 4–27. doi: 10.1093/neuonc/nos273.

9. Weller M, Reifenberger G, Le Rhun E et al. Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419). J Clin Oncol 2019; 37 (suppl 15) 2056–2056. doi: 10.1200/JCO.2019.37.15_suppl. 2056.

10. Barani IJ, Larson DA. Radiation therapy of glioblastoma. Cancer Treat Res 2015; 163: 49–73. doi: 10.1007/978-3-319-12048-5_4.

11. Pöhlmann J, Weller M, Marcellusi A et al. High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma. Front Oncol 2024; 14: 1368606. doi: 10.3389/fonc.2024.1368606.

12. Perlow HK, Prasad RN, Yang M et al. Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: a pooled analysis of patient-level data from 4 prospective trials. Cancer 2022; 128 (12): 2367–2374. doi: 10.1002/cncr.34192.

13. MacDonald SM, Ahmad S, Kachris S, Vogds BJ et al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high-grade glioma: a dosimetric comparison. J Appl Clin Med Phys 2007; 8 (2): 47–60. doi: 10.1120/jacmp.v8i2.2423.

14. Perry JR, Laperriere N, O‘Callaghan CJ et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 2017; 376 (11): 1027–1037. doi: 10.1056/NEJMoa1611977.

15. Minniti G, Scaringi C, Lanzetta G et al. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int J Radiat Oncol Biol Phys 2015; 91 (1): 109–115. doi: 10.1016/j.ijrobp.2014.09.013.

16. König L, Jäkel C, von Knebel Doeberitz N. Glioblastoma radiotherapy using intensity modulated Radiotherapy (IMRT) or proton radiotherapy – GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III study. Radiat Oncol 2021; 16: 240. doi: 10.1186/s13014-021-01962-8.

17. Barbagallo GM, Jenkinson MD, Brodbelt AR. Recurrent‘ glioblastoma multiforme, when should we reoperate? Br J Neurosurg 2008; 22 (3): 452–455. doi: 10.1080/02688690802182256.

18. Franceschi E, Bartolotti M, Tosoni A et al. The effect of re-operation on survival in patients with recurrent glioblastoma. Anticancer Res 2015; 35 (3): 1743–1748.

19. Taal W, Oosterkamp HM, Walenkamp AM et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014; 15 (9): 943–953. doi: 10.1016/S1470-2045 (14) 70314-6.

20. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27 (28): 4733–4740. doi: 10.1200/JCO.2008.19.8721.

21. Wick W, Gorlia T, Bendszus M et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 2017; 377 (20): 1954–1963. doi: 10.1056/NEJMoa1707358.

22. Mireștean CC, Iancu RI, Iancu DPT. New horizons in modulating the radio-sensitivity of head and neck cancer – 100 years after Warburg‘ effect discovery. Front Oncol 2022; 12: 908695. doi: 10.3389/fonc.2022.908695.

23. Franceschi E, Lamberti G, Visani M et al. Temozolomide rechallenge in recurrent glioblastoma: when is it useful? Future Oncol 2018; 14 (11): 1063–1069. doi: 10.2217/fon-2017-0681.

24. Batchelor TT, Mulholland P, Neyns B et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013; 31 (26): 3212–3218. doi: 10.1200/JCO.2012.47.2464.

25. Alexander BM, Ba S, Berger MS et al. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin Cancer Res 2018; 24 (4): 737–743. doi: 10.1158/1078-0432.CCR-17-0764.

26. Perry JR, Rizek P, Cashman R et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach. Cancer 2008; 113 (8): 2152–2157. doi: 10.1002/cncr. 23813.

27. Wick A, Pascher C, Wick W et al. Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 2009; 256 (5): 734–741. doi: 10.1007/s00415-009- 5006-9.

28. Wong ET, Lok E, Swanson KD. Alternating electric fields therapy for malignant gliomas: from bench Observation to clinical reality. Prog Neurol Surg 2018; 32: 180–195. doi: 10.1159/000469690.

29. Kesari S, Ram Z; EF-14 Trial Investigators. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. CNS Oncol 2017; 6 (3): 185–193. doi: 10.2217/cns-2016-0049.

30. Chen L, Han L, Shi Z et al. LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. Mol Med Rep 2012; 5 (2): 575–579. doi: 10.3892/mmr.2011.674.

31. Cardona AF, Jaramillo-Velásquez D, Ruiz-Patiño A et al. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation. J Neurooncol 2021; 154 (3): 353–364. doi: 10.1007/s11060-021-03834-3.

32. Awada G, Ben Salama L, De Cremer J et al. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). J Immunother Cancer 2020; 8 (2): e001146. doi: 10.1136/jitc-2020-001146.

33. Olivet MM, Brown MC, Reitman ZJ et al. Clinical applications of immunotherapy for recurrent glioblastoma in adults. Cancers (Basel) 2023; 15 (15): 3901. doi: 10.3390/cancers15153901.

34. Rahman R, Preusser M, Tsien C et al. The role of reirradiation in recurrent glioblastoma. Neuro-Oncology 2024: noae209. doi: 10.1093/neuonc/noae209.

35. Shanker M, Chua B, Bettington C et al. Re-irradiation for recurrent high-grade gliomas: a systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis. Neurooncol Pract 2019; 6 (2): 144–155. doi: 10.1093/nop/npy019.

36. Gigliotti MJ, Hasan S, Karlovits SM et al. Re-irradiation with stereotactic radiosurgery/radiotherapy for recurrent high-grade gliomas: improved survival in the modern era. Stereotact Funct Neurosurg 2018; 96 (5): 289–295. doi: 10.1159/000493545.

37. Grosu AL, Weber WA, Franz M et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT) /CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63 (2): 511–519. doi: 10.1016/j.ijrobp.2005.01.056.

38. Oehlke O, Mix M, Graf E et al. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer 2016; 16 (1): 769. doi: 10.1186/s12885-016-2806-z.

39. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA). [online]. Available from: https: //clinicaltrials.gov/study/NCT01252459?cond=NCT01252459&rank=1.

40. Gregucci F, Surgo A, Carbonara R et al. Radiosurgery and stereotactic brain radiotherapy with systemic therapy in recurrent high-grade gliomas: is it feasible? Therapeutic strategies in recurrent high-grade gliomas. J Pers Med 2022; 12 (8): 1336. doi: 10.3390/jpm12081336.

41. Mireștean CC, Iancu RI, Iancu DPT. Micro-RNAs, the cornerstones of the future of radiobiology in head and neck cancers? Curr Oncol 2022; 29 (2): 816–833. doi: 10.3390/curroncol29020069.

42. Minniti G, Niyazi M, Alongi F et al. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 2021; 16 (1): 36. doi: 10.1186/s13014-021- 01767-9.

43. Buzea CG, Mirestean C, Butuc I et al. Radiation-induced biological changes of neural structures in the base of the skull tumours. J Radiother Prac 2017; 16 (2): 183–198. doi: 10.1017/S1460396916000601.

44. Fleischmann DF, Jenn J, Corradini S et al. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. Radiother Oncol 2019; 138: 99–105. doi: 10.1016/j.radonc.2019.06.009.

45. Popp I, Weber A, Graf E et al. Re-irradiation in recurrent glioblastoma: PET- or MRI-based? Results of a prospective randomized clinical trial. J Clin Oncol 2024; 42: 2021–2021. doi: 10.1200/JCO.2024.42.16_suppl.2021.

46. Grosu A, Weber A, Graf E et al. GLIAA: FET-PET- vs. MRI-based re-irradiation in recurrent glioblastoma. A prospective randomized trial. J Nucl Med 2024; 65 (suppl 2): 242119.

47. Andratschke N, Heusel A, Albert NL et al. ESTRO/EANO recommendation on reirradiation of glioblastoma. Radiother Oncol 2025; 204: 110696. doi: 10.1016/j.radonc.2024.110696.

48. Preusser M, Kazda T, Le Rhun E et al. Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study. Trials 2024; 25 (1): 366. doi: 10.1186/s13063-024-08213-7.